Last reviewed · How we verify
OCTREOSCAN (INDIUM IN-111 PENTETREOTIDE KIT)
OCTREOSCAN (generic name: INDIUM IN-111 PENTETREOTIDE KIT) is a drug developed by CURIUM. It is currently FDA-approved.
OCTREOSCAN, also known as Yttrium Y 90-edotreotide, is used to treat various conditions including Breast Cancer, Lung Cancer, Sarcoidosis, Solid Tumors, and Neuroendocrine Carcinoma. It is a radiolabeled compound that contains Yttrium Y 90, which is attached to the peptide edotreotide.
At a glance
| Generic name | INDIUM IN-111 PENTETREOTIDE KIT |
|---|---|
| Sponsor | CURIUM |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Nausea
- Injection site pain
- Diarrhea
- Abdominal pain/discomfort
- Loose stools
- Vomiting
- Dizziness
- Fever
- Flush
- Headache
- Hypotension
- Changes in liver enzymes
Serious adverse events
- Bradycardia
- Decreased hematocrit
- Decreased hemoglobin
- Angioedema
- Anaphylaxis
- Hypersensitivity reactions
Key clinical trials
- A Phase II, Open-label, Multi-Center Study to Evaluate the Efficacy of 90Y-SMT 487 Administered Intravenously to Patients With Refractory Small Cell Lung or Advanced Metastatic Breast Cancer Expressin (Phase 2)
- A Randomized Phase III of Adjuvant Targeted Radionuclide Therapy With In111-Pentetreotide in Patients With Digestive Neuroendocrine Tumors After Complete Surgical Resection of Liver Metastases. (Phase 3)
- A Phase I Study of [111In-DTPA-D-Phe]-Octreotide in Patients With Refractory Malignancies Expressing Somatostatin Receptors (Phase 1)
- Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis (NA)
- An Open-Label, Multi-Center, Phase 4 Study to Evaluate the Effect of Age (Geriatric) and Renal Function on the Safety, Efficacy (Sensitivity, Specificity) and Pharmacokinetics of OctreoScan in Patient (Phase 4)
- Use of 68Ga-DOTATATE PET Scanning for Diagnosis and Treatment of Metastatic Neuroendocrine Tumors (Phase 2)
- Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors (Phase 1)
- A Prospective Evaluation of the Management of Sporadic Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Neoplasms ≤ 2 cm (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OCTREOSCAN CI brief — competitive landscape report
- OCTREOSCAN updates RSS · CI watch RSS
- CURIUM portfolio CI
Frequently asked questions about OCTREOSCAN
What is OCTREOSCAN?
Who makes OCTREOSCAN?
What is the generic name of OCTREOSCAN?
What development phase is OCTREOSCAN in?
What are the side effects of OCTREOSCAN?
Related
- Manufacturer: CURIUM — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing